U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder
Reuters2022-09-17
Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.
"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys" with early, active Cerebral Adrenoleukodystrophy $(CALD)$, the company said in a statement, saying CALD is a "devastating and fatal neurodegenerative disease."
(Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)
((mrinalika.roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
